Vaxcyte (PCVX) Total Non-Current Liabilities (2019 - 2025)

Vaxcyte (PCVX) has 7 years of Total Non-Current Liabilities data on file, last reported at $317.1 million in Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $317.1 million, up 54.39% year-over-year; the trailing twelve-month figure through Dec 2025 was $317.1 million (up 54.39% YoY), and the FY2025 annual result was $317.1 million, up 54.39% from the prior year.
• Total Non-Current Liabilities climbed to $317.1 million in Q4 2025 per PCVX's latest filing, from $205.4 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $317.1 million in Q4 2025 and troughed at $40.2 million in Q4 2021.
• A 5-year average of $92.4 million and a median of $54.0 million in 2021 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities declined 22.11% in 2022, then surged 218.61% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $40.2 million in 2021, then soared by 30.66% to $52.6 million in 2022, then surged by 218.61% to $167.4 million in 2023, then rose by 22.66% to $205.4 million in 2024, then surged by 54.39% to $317.1 million in 2025.
• Business Quant data shows PCVX's Total Non-Current Liabilities at $317.1 million in Q4 2025, $205.4 million in Q4 2024, and $167.4 million in Q4 2023.